Scarica l'app Stockscreener
84.81
1.10%
0.92
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$83.89
Aprire:
$83.83
Volume 24 ore:
1.25M
Relative Volume:
0.72
Capitalizzazione di mercato:
$16.56B
Reddito:
$4.58B
Utile/perdita netta:
$870.87M
Rapporto P/E:
19.27
EPS:
4.4
Flusso di cassa netto:
$945.58M
1 W Prestazione:
+0.32%
1M Prestazione:
+0.24%
6M Prestazione:
+40.07%
1 anno Prestazione:
+28.31%
Intervallo 1D:
$83.75
$85.31
Intervallo di 1 settimana:
$81.09
$85.31
Portata 52W:
$53.56
$87.99
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
84.81 | 16.38B | 4.58B | 870.87M | 945.58M | 4.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Poinciana Advisors Group LLC Makes New Investment in Incyte Corporation $INCY - MarketBeat
Patton Albertson Miller Group LLC Acquires 5,497 Shares of Incyte Corporation $INCY - MarketBeat
Patton Fund Management Inc. Takes $254,000 Position in Incyte Corporation $INCY - MarketBeat
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication - GlobeNewswire Inc.
Candlestick signals on Incyte Corporation stock todayJuly 2025 Action & Daily Profit Focused Stock Screening - newser.com
Will Incyte Corporation stock outperform value stocks2025 EndofYear Setup & Technical Confirmation Alerts - newser.com
Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions - Yahoo Finance
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN
How to use Fibonacci retracement on Incyte CorporationJuly 2025 Weekly Recap & Accurate Buy Signal Notifications - newser.com
Jim Cramer Calls Incyte “Way Too Cheap” - Yahoo Finance
Ruffer LLP Sells 9,988 Shares of Incyte Corporation $INCY - MarketBeat
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 24, 2025 - biospace.com
RBC Capital Raises Price Target for Incyte (INCY) to USD 81 | IN - GuruFocus
Incyte stock price target raised to $81 from $72 at RBC Capital - Investing.com
Guggenheim Reaffirms "Neutral" Rating for Incyte (NASDAQ:INCY) - MarketBeat
Incyte’s Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions - Insider Monkey
Mn Services Vermogensbeheer B.V. Sells 6,600 Shares of Incyte Corporation $INCY - MarketBeat
Is Incyte Stock Outperforming The S&P 500? - Barchart.com
Incyte Corporation (NASDAQ:INCY) Short Interest Down 21.8% in August - MarketBeat
Incyte Corporation $INCY Stake Lowered by Diversified Trust Co - MarketBeat
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer - BioSpace
NorthCrest Asset Manangement LLC Has $777,000 Stock Holdings in Incyte Corporation $INCY - MarketBeat
Sovran Advisors LLC Sells 12,174 Shares of Incyte Corporation $INCY - MarketBeat
Is Incyte Corporation a candidate for recovery playJuly 2025 Levels & Proven Capital Preservation Tips - newser.com
Incyte (NASDAQ:INCY) Price Target Raised to $115.00 at Stifel Nicolaus - MarketBeat
Stifel Raises Price Target for Incyte (INCY) to $115 While Maint - GuruFocus
Incyte appoints Dave Gardner as new chief strategy officer - Investing.com
Stifel Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $115 - 富途牛牛
Incyte’s SWOT analysis: stock outlook mixed amid pipeline progress, jakafi concerns - Investing.com
Incyte stock price target raised to $115 by Stifel on pediatric approval - Investing.com
Incyte (NASDAQ:INCY) EVP Sells $23,115.70 in Stock - MarketBeat
Pallas Capital Advisors LLC Reduces Holdings in Incyte Corporation $INCY - MarketBeat
Perpetual Ltd Purchases New Holdings in Incyte Corporation $INCY - MarketBeat
34,082 Shares in Incyte Corporation $INCY Acquired by Strs Ohio - MarketBeat
How Investors May Respond To Incyte (INCY) Expanding Opzelura’s Pediatric Use Following FDA Approval - Yahoo Finance
Swedbank AB Raises Stock Holdings in Incyte Corporation $INCY - MarketBeat
Baader Bank Aktiengesellschaft Invests $424,000 in Incyte Corporation $INCY - MarketBeat
4,558 Shares in Incyte Corporation $INCY Purchased by OMNI 360 Wealth Inc. - MarketBeat
Incyte Corporation (NASDAQ:INCY) Given Average Rating of "Hold" by Brokerages - MarketBeat
Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink? - MSN
Guggenheim Reiterates Neutral Rating for Incyte (INCY) | INCY Stock News - GuruFocus
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - Yahoo Finance
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In ChildrenIncyte (NASDAQ:INCY) - Benzinga
Incyte (NASDAQ:INCY) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Invst LLC Makes New $315,000 Investment in Incyte Corporation $INCY - MarketBeat
CEO Change: Is Incyte Corporation showing insider buyingMarket Activity Summary & Advanced Technical Signal Analysis - خودرو بانک
Loss Report: What is the next catalyst for Incyte CorporationJuly 2025 Decliners & Target Return Focused Stock Picks - خودرو بانک
FDA approves Opzelura for atopic dermatitis in children ages 2 and up - Investing.com
US FDA approves Incyte's eczema cream for pediatric patients - Reuters
FDA Greenlights Incyte's Opzelura Cream for Pediatric Dermatitis Treatment - GuruFocus
FDA Approves Incyte's (INCY) Opzelura Cream for Pediatric Dermatitis - GuruFocus
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
4.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):